Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.39 is 77% below its 5-year average of 1.69, near the low end of its 5-year range (-0.35–4.75).
80.84% below its 12-month average of 2.04.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.23.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:01:16.797Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.39
EARNINGS PER SHARE (EPS) AVG TTM
2.04
EARNINGS PER SHARE (EPS) AVG 3Y
1.43
EARNINGS PER SHARE (EPS) AVG 5Y
1.69
EARNINGS PER SHARE (EPS) AVG 10Y
0.36
EARNINGS PER SHARE (EPS) AVG 15Y
-0.16
EARNINGS PER SHARE (EPS) AVG 20Y
0.01
CURRENT VS TTM AVG
-80.84%
CURRENT VS 3Y AVG
-72.73%
CURRENT VS 5Y AVG
-76.88%
CURRENT VS 10Y AVG
+6.98%
CURRENT VS 15Y AVG
+345.80%
CURRENT VS 20Y AVG
+5006.82%
BioMarin Pharmaceutical Inc.
Market Cap
$10.98B
Earnings Per Share (EPS)
0.39
TTM Avg
2.04
3Y Avg
1.43
5Y Avg
1.69
Market Cap
$11.00B
Earnings Per Share (EPS)
2.93
TTM Avg
1.92
3Y Avg
1.82
5Y Avg
4.51
Market Cap
$10.75B
Earnings Per Share (EPS)
24.38
TTM Avg
20.29
3Y Avg
15.04
5Y Avg
13.87
Market Cap
$11.35B
Earnings Per Share (EPS)
1.16
TTM Avg
0.82
3Y Avg
1.13
5Y Avg
1.19
Market Cap
$10.41B
Earnings Per Share (EPS)
-0.97
TTM Avg
-0.48
3Y Avg
-0.79
5Y Avg
-0.77
Market Cap
$11.53B
Earnings Per Share (EPS)
-12.89
TTM Avg
-17.38
3Y Avg
-17.99
5Y Avg
-16.61
Market Cap
$10.35B
Earnings Per Share (EPS)
3.89
TTM Avg
2.37
3Y Avg
1.93
5Y Avg
1.71
Market Cap
$10.26B
Earnings Per Share (EPS)
5.76
TTM Avg
5.64
3Y Avg
5.43
5Y Avg
9.01
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc. (BMRN) | $10.98B | 0.39 | 2.04 | 1.43 | 1.69 |
| The Cooper Companies, Inc. (COO)vs › | $11.00B | 2.93 | 1.92 | 1.82 | 4.51 |
| Universal Health Services, Inc. (UHS)vs › | $10.75B | 24.38 | 20.29 | 15.04 | 13.87 |
| Bio-Techne Corporation (TECH)vs › | $11.35B | 1.16 | 0.82 | 1.13 | 1.19 |
| ImmunityBio, Inc. (IBRX)vs › | $10.41B | -0.97 | -0.48 | -0.79 | -0.77 |
| Madrigal Pharmaceuticals, Inc. (MDGL)vs › | $11.53B | -12.89 | -17.38 | -17.99 | -16.61 |
| Globus Medical, Inc. (GMED)vs › | $10.35B | 3.89 | 2.37 | 1.93 | 1.71 |
| DaVita Inc. (DVA)vs › | $11.67B | 11.38 | 10.37 | 8.56 | 8.35 |
| Align Technology, Inc. (ALGN)vs › | $10.26B | 5.76 | 5.64 | 5.43 | 9.01 |
| Repligen Corporation (RGEN)vs › | $10.12B | 0.73 | 0.20 | 1.10 | 1.31 |
Trailing EPS (TTM)
$0.39
Forward EPS (Est.)
$5.00
P/E Ratio
145.7
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 1.82 |
| 2024-12-31 | 2.25 |
| 2023-12-31 | 0.89 |
| 2022-12-31 | 0.76 |
| 2021-12-31 | -0.35 |
| 2020-12-31 | 4.75 |
| 2019-12-31 | -0.13 |
| 2018-12-31 | -0.44 |
| 2017-12-31 | -0.67 |
| 2016-12-31 | -3.80 |
| 2015-12-31 | -1.07 |
| 2014-12-31 | -0.92 |
| 2013-12-31 | -1.28 |
| 2012-12-31 | -0.95 |
| 2011-12-31 | -0.48 |
| 2010-12-31 | 1.99 |
| 2009-12-31 | 0.00 |
| 2008-12-31 | 0.31 |
| 2007-12-31 | -0.16 |
| 2006-12-31 | -0.34 |
| 2005-12-31 | -1.08 |
| 2004-12-31 | -2.91 |
| 2003-12-31 | -1.22 |
| 2002-12-31 | -1.45 |
| 2001-12-31 | -1.65 |
| 2000-12-31 | -1.04 |
| 1999-12-31 | -0.94 |
| 1998-12-31 | -0.55 |
